Seminars & Events
Friday, October 4, 2013: Dr. Laurie Ryan, SMCM '86 (National Institute on Aging) will speak on "Alzheimer's Disease: Targets and Treatments" at 3:00 pm in Goodpaster Hall 195.
Monday, October 21, 2013: Dr. Greg Elmer (University of Maryland Baltimore) will speak on "Domains and Constructs in Motivation: Where Does the Habenula Fit In?" at 4:45 pm in Goodpaster Hall 195.
Friday, October 25, 2013: Dr. Terry Davidson (American University) will speak on "Why We Overeat and Become Obese? It Could be What We Think!" at 3:00 pm in Goodpaster Hall 195.
Dr. Gwen Calhoon '06 recently received her Ph.D. in Neuroscience from the University of Maryland Baltimore, and was inducted into Nu Rho Psi.
Tracy, Megan (2011). Investigating the efficacy of antipsychotic drug treatment on an animal model of schizophrenia. (Mentor: A. Bailey)
Schizophrenia is a disease that is difficult to study and understand due to its variety of symptoms and difficulty to fully treat. The most common treatment for the symptoms of schizophrenia is psychopharmaceutical therapy. Olanzapine is an atypical antipsychotic that is often prescribed for schizophrenia in adults and adolescents. Fifty-six long evans rats were used to test the effects of adolescent olanzapine administration in the NVHL animal model of schizophrenia. The animals’ play behavior was tested during adolescence while they were receiving either olanzapine or vehicle in their drinking water. In adulthood, the rats were tested for disrupted sensory gating and hyperlocomotion. The animals did not show significant differences in the prepulse inhibition task or the hyperlocomotion task. These results suggest that a different dose of olanzapine is necessary to see differences between the animal groups. There were significant differences seen during the adolescent play behavior, showing significantly increased play behavior in the control animals.